Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2026. "We delivered 29% revenue growth in the third quarter, alongside the U.S. approval of mFLUSIVA, our fifth approved product globally, and positive Phase 3 results for intismeran in melanoma," said Stéphane Bancel, Chief Executive Officer of Moderna. "Building on this momentum, we increased our full-year revenue growth outlook...
Read more








